Neutralizing assay raw data.

To address the need for multivalent vaccines against Coronaviridae that can be rapidly developed and manufactured, we compared antibody responses against SARS-CoV, SARS-CoV-2, and several variants of concern in mice immunized with mRNA-lipid nanoparticle vaccines encoding homodimers or heterodimers of SARS-CoV/SARS-CoV-2 receptor-binding domains. All vaccine constructs induced robust anti-RBD antibody responses, and the heterodimeric vaccine elicited an IgG response capable of cross-neutralizing SARS-CoV, SARS-CoV-2 Wuhan-Hu-1, B.1.351 (beta), and B.1.617.2 (delta) variants.

为满足可快速研发与制造的冠状病毒科（Coronaviridae）多价疫苗的需求，我们针对接种了编码严重急性呼吸综合征冠状病毒（SARS-CoV）/新型冠状病毒（SARS-CoV-2）受体结合域（receptor-binding domain, RBD）同源二聚体或异二聚体的mRNA脂质纳米颗粒（mRNA-lipid nanoparticle）疫苗的小鼠，对比分析了其针对SARS-CoV、SARS-CoV-2及多种关切变异株的抗体应答。所有疫苗构建体均可诱导强效的抗RBD抗体应答，且该异二聚体疫苗诱导产生的IgG抗体可交叉中和SARS-CoV、SARS-CoV-2 Wuhan-Hu-1株、B.1.351（Beta株）及B.1.617.2（Delta株）变异株。